Biomea Fusion (NASDAQ: BMEA) — Company Overview, News & Financial Data
Biomea Fusion is a biotech company developing covalent small molecules for cancer treatment aimed at improving patient outcomes.

Biomea Fusion
Biomea Fusion (NASDAQ:BMEA) is a dynamic biotech company focused on discovering and developing innovative treatments for patients battling cancer and other grave diseases. Their projects primarily involve the investigation of novel covalent small molecules that can potentially offer transformative outcomes in the field of oncology and beyond. With a commitment to advancing science and improving lives, Biomea Fusion's objectives encompass the successful progression of their drug candidates through clinical trials, aiming for breakthrough therapies that can meaningfully improve patient outcomes. At the heart of their operations is a dedication to leveraging cutting-edge science to address unmet medical needs, identifying and targeting critical pathways in disease mechanisms.
Snapshot
Operations
Products and/or services of Biomea Fusion
- Covalent menin inhibition technology, targeting a range of cancers.
- BMF-219, an oral small molecule, focused on difficult-to-treat cancers.
- Preclinical programs studying the potential in a variety of solid and hematologic malignancies.
- Collaborations aimed at advancing precision oncology treatments.
- Research into the molecular drivers of disease to inform future therapies.
- Development of biomarker-driven approaches to match patients with the most effective treatments.
Biomea Fusion executive team
- Michael J. M. HitchcockInterim CEO & Director
- Ramses M. ErdtmannCo-Founder, President, COO & Director
- Heow TanChief Technical & Quality Officer
- Caroline Perez- DupontSenior Vice President of Legal
- Thorsten KirschbergExecutive Vice President of Research
- Stephan MorrisChief Development Officer
- Ravi UpasaniExecutive Vice President of Intellectual Property
Recent announcements
What Biomea Fusion (BMEA) has told the market, newest first.
Key financials
Reported results for Biomea Fusion, in USD.
- Market cap
- 42.8M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -81.3M | -61.8M | |
| 0 | -144.1M | -138.4M | |
| 0 | -126.1M | -117.3M | |
| 0 | -83.6M | -80M |